YHB Investment Advisors Inc. cut its stake in Novartis AG (NYSE:NVS) by 4.5% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,353 shares of the company’s stock after selling 250 shares during the period. YHB Investment Advisors Inc.’s holdings in Novartis were worth $489,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors also recently modified their holdings of NVS. Primecap Management Co. CA grew its stake in shares of Novartis by 4.2% in the first quarter. Primecap Management Co. CA now owns 23,857,216 shares of the company’s stock worth $2,293,633,000 after purchasing an additional 969,985 shares in the last quarter. FMR LLC grew its stake in shares of Novartis by 23.7% in the first quarter. FMR LLC now owns 8,678,552 shares of the company’s stock worth $834,356,000 after purchasing an additional 1,662,505 shares in the last quarter. Mawer Investment Management Ltd. grew its stake in shares of Novartis by 19.2% in the first quarter. Mawer Investment Management Ltd. now owns 5,680,653 shares of the company’s stock worth $546,138,000 after purchasing an additional 916,167 shares in the last quarter. Janus Henderson Group PLC grew its stake in shares of Novartis by 11.1% in the first quarter. Janus Henderson Group PLC now owns 3,717,495 shares of the company’s stock worth $357,400,000 after purchasing an additional 371,396 shares in the last quarter. Finally, Lazard Asset Management LLC grew its stake in shares of Novartis by 407.4% in the first quarter. Lazard Asset Management LLC now owns 2,525,897 shares of the company’s stock worth $242,839,000 after purchasing an additional 2,028,045 shares in the last quarter. 11.85% of the stock is currently owned by hedge funds and other institutional investors.
NVS stock traded up $0.68 during trading hours on Thursday, hitting $92.26. 33,737 shares of the stock traded hands, compared to its average volume of 2,166,748. The firm has a 50-day moving average of $91.41. Novartis AG has a one year low of $71.33 and a one year high of $95.00. The firm has a market capitalization of $210.54 billion, a P/E ratio of 18.12, a P/E/G ratio of 2.10 and a beta of 0.59. The company has a current ratio of 0.94, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43.
Several research analysts have recently issued reports on NVS shares. Argus increased their price target on Novartis to $105.00 and gave the stock a “buy” rating in a research note on Tuesday, July 23rd. They noted that the move was a valuation call. Morgan Stanley cut Novartis from an “equal weight” rating to an “underweight” rating and increased their price target for the stock from $82.50 to $82.52 in a research note on Wednesday, April 10th. Kepler Capital Markets cut Novartis from a “buy” rating to a “hold” rating in a research note on Tuesday, July 23rd. Guggenheim raised Novartis from a “neutral” rating to a “buy” rating and set a $79.16 target price for the company in a research note on Wednesday, April 24th. Finally, Liberum Capital raised Novartis from a “hold” rating to a “buy” rating in a research note on Thursday, April 25th. Four analysts have rated the stock with a sell rating, five have assigned a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $90.63.
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardio-metabolic, and established medicine products.
Featured Story: What are the benefits of momentum investing?
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.